EGA 2017 PRISM Track
With an introduction by PRISM (Psychedelic Research in Science & Medicine) president Martin Williams
The PRISM Track Program consists of:
FROM ADAM TO ECSTASY TO FDA-APPROVED MDMA-ASSISTED PSYCHOTHERAPY
MDMA PSYCHOTHERAPY: A CHILD PSYCHIATRIST’S PERSPECTIVE
KETAMINE'S THERAPEUTIC POTENTIAL
Perspectives - An introduction to Psychedelic research in Australia
Psychedelic Research in 60´s: Teachings and Implications for Future
RESEARCHING MEDICAL CANNABIS: NAVIGATING BARRIERS TO EFFICACY RESEARCH
PRISM was founded in Australia as an incorporated non-profit research association in March 2011 and is a government approved tax-exempt charity. Our purpose is to investigate whether psychedelic compounds, while being powerful psychoactive agents that should be approached with enormous respect, are also potential medicines that may be employed to achieve significant positive outcomes in the treatment of a range of diseases for which conventional medicines provide limited relief.
The word ‘psychedelic’ was explicitly included in the name of our organisation in the hope of encouraging more widespread familiarity, removing the mystery of the unknown, addressing the social stigma still attached to psychedelics and ultimately according them value and respect.
PRISM is closely aligned with our USA based collaborative partner, the Multidisciplinary Association for Psychedelic Studies (MAPS).